Three specific companies are poised to benefit from the expanding market for GLP-1 medications beyond dominant players like Novo Nordisk and Eli Lilly.

Full report: https://www.procapinsights.com/

ProCap Insights is a research division of ProCap Financial. This podcast is for informational and analytical purposes only. It does not constitute individualized financial, investment, tax, legal, accounting, or other professional advice. You should consult with qualified professionals before making significant financial decisions. You are solely responsible for any decisions you make using or based on information provided herein. Nothing in this podcast should be construed as a solicitation or recommendation to buy or sell any financial instrument.